+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Endometrial Hyperplasia Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767394
  • Report
  • April 2019
  • Region: Global
  • 51 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • 3M Drug Delivery Systems
  • Bayer AG
  • Ferring Holding SA
  • Novartis AG
  • Pfizer Inc
  • QPS Holdings LLC
  • MORE
The global clinical trial report- “2019 Endometrial Hyperplasia Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Endometrial Hyperplasia. It presents in-depth analysis of Endometrial Hyperplasia clinical trials across markets and companies. The research work is for providing complete understanding into trends in Endometrial Hyperplasia.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Endometrial Hyperplasia clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Endometrial Hyperplasia

The research work is prepared through extensive and continuous research on Endometrial Hyperplasia trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Endometrial Hyperplasia patients are identified
  • The report includes panorama of Endometrial Hyperplasia clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Endometrial Hyperplasia clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 3M Drug Delivery Systems
  • Bayer AG
  • Ferring Holding SA
  • Novartis AG
  • Pfizer Inc
  • QPS Holdings LLC
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Endometrial Hyperplasia Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Endometrial Hyperplasia Clinical Trials by Region
2.2.2 Average Enrollment of Endometrial Hyperplasia Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Endometrial Hyperplasia Treatment, 2019

3. Region wise Endometrial Hyperplasia Clinical Trials
3.1 Asia Pacific Endometrial Hyperplasia Clinical Trials by Country
3.2 Europe Endometrial Hyperplasia Clinical Trials by Country
3.3 North America Endometrial Hyperplasia Clinical Trials by Country
3.4 Middle East and Africa Endometrial Hyperplasia Clinical Trials by Country
3.5 South and Central America Endometrial Hyperplasia Clinical Trials by Country

4. Endometrial Hyperplasia Clinical Trial Trends
4.1 Start Year wise Endometrial Hyperplasia Clinical Trials
4.2 Phase wise Endometrial Hyperplasia Clinical Trials
4.3 Trial Status wise Endometrial Hyperplasia Clinical Trials
4.4 Trial Type wise Endometrial Hyperplasia Clinical Trials

5. Endometrial Hyperplasia Average Enrollment Trends
5.1 Average Enrollment in Endometrial Hyperplasia Trials by Year
5.2 Average Enrollment in Endometrial Hyperplasia Trials by Phase
5.3 Average Enrollment in Endometrial Hyperplasia Trials by Status
5.4 Average Enrollment in Endometrial Hyperplasia Trials by Type of Trial

6. Companies Participating in Endometrial Hyperplasia Clinical Trials
6.1 Endometrial Hyperplasia Trials by Sponsor Type
6.2 Endometrial Hyperplasia Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Endometrial Hyperplasia Trials- Phase 1
7.2 Endometrial Hyperplasia Trials- Phase 2
7.3 Endometrial Hyperplasia Trials- Phase 3
7.4 Endometrial Hyperplasia Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Endometrial Hyperplasia Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Endometrial Hyperplasia Clinical Trials and Enrolment
Figure 5: Europe - Country wise Endometrial Hyperplasia Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Endometrial Hyperplasia Clinical Trials and Enrolment
Figure 7: North America - Country wise Endometrial Hyperplasia Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Endometrial Hyperplasia Clinical Trials and Enrolment
Figure 9: Endometrial Hyperplasia Clinical Trials by Phase
Figure 10: Endometrial Hyperplasia Clinical Trials by Trial Status
Figure 11: Endometrial Hyperplasia Clinical Trials by Type
Figure 12: Endometrial Hyperplasia Clinical Trials by Sponsor Type
Figure 13: Endometrial Hyperplasia Clinical Trials by Leading Sponsors
Figure 14: Endometrial Hyperplasia Average Enrollment by Phase
Figure 15: Endometrial Hyperplasia Average Enrollment by Trial Status
Figure 16: Endometrial Hyperplasia Average Enrollment by Type
Figure 17: Endometrial Hyperplasia- Average Enrolment by Type of Sponsors
Figure 18: Endometrial Hyperplasia- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Endometrial Hyperplasia Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Endometrial Hyperplasia Clinical Trials and Enrolment
Table 5: Europe - Country wise Endometrial Hyperplasia Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Endometrial Hyperplasia Clinical Trials and Enrolment
Table 7: North America - Country wise Endometrial Hyperplasia Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Endometrial Hyperplasia Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Endometrial Hyperplasia Average Enrollment by Phase
Table 15: Endometrial Hyperplasia Average Enrollment by Trial Status
Table 16: Endometrial Hyperplasia Average Enrollment by Type
Table 17: Endometrial Hyperplasia- Average Enrolment by Type of Sponsors
Table 18: Endometrial Hyperplasia- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 3M Drug Delivery Systems
  • Bayer AG
  • Ferring Holding SA
  • Novartis AG
  • Pfizer Inc
  • QPS Holdings LLC
  • Sumitomo Dainippon Pharma Co Ltd
  • Teva Pharmaceutical Industries Ltd
Note: Product cover images may vary from those shown
Adroll
adroll